Trial studying safety and effects for Diffuse Astrocytoma, IDH-Mutant
Official title Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
ClinicalTrials.gov ID: NCT06047379
What this study is testing
What is NEO212 Oral Capsule?
An investigational oral capsule being studied for the treatment of certain brain tumors such as diffuse astrocytoma, IDH‑mutant and glioblastoma.
Also referred to as POH‑TMZ.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study aims to determine how safe NEO212 is, how it behaves in the body, and whether it can help treat brain tumors and other cancers.
- Who it's for
- Adults who have a confirmed progression of astrocytoma (IDH‑mutant), glioblastoma (IDH‑wildtype), or brain metastases from solid tumors.
- What's involved
- Participants will receive repeated doses of NEO212, either alone or together with standard cancer treatments, and will have regular medical visits and tests to monitor safety and effectiveness.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Patient must be ≥ 18yrs of age.
- Patient must have the ability to understand, and the willingness to sign, a written informed consent form.
- Patient has been on a stable or decreasing dose of steroids for at least five days prior to the date of informed consent.
- Any toxicity from prior therapy must be resolved or at maximum Grade 1 prior to initiation of NEO212.
- If progression of disease occurs within 90 days or conformal radiation, the progression/recurrence must be outside of the radiation field or proven...
You likely can't join if
- (all Phases)
- Patient in Phase 1 concurrently receiving any other antitumor therapy.
- Patient in Phase 2a or 2b who is concurrently receiving any SOC therapy not listed in Appendix 1.
- Patients with metastases to the spinal cord parenchyma.
- Patients with metastases to the meninges.
- Patient has received stereotactic or highly conformal radiotherapy to CNS lesions within 2 weeks before receipt of NEO212.
See the full eligibility criteria
Who can join
- Patient must be ≥ 18yrs of age.
- Patient must have the ability to understand, and the willingness to sign, a written informed consent form.
- Patient has been on a stable or decreasing dose of steroids for at least five days prior to the date of informed consent.
- Any toxicity from prior therapy must be resolved or at maximum Grade 1 prior to initiation of NEO212.
- If progression of disease occurs within 90 days or conformal radiation, the progression/recurrence must be outside of the radiation field or proven by biopsy/resection.
- Patient with Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype must have a Karnofsky Performance Status (KPS) of ≥ 60.
- Patient with select solid tumors must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
- Patient must have an expected survival or at least three months.
- Patient must have a baseline MRI of the brain with gadolinium within 14 days of administration of NEO212.
- Patient with select solid tumors must have a baseline CT scan with IV contrast and oral contrast of neck, chest, abdomen and pelvis within 14 days of administration of NEO212.
- Patients must be able to comply with all study assessments.
- If patient suffers from seizures (s)he must be controlled on a stable dose of anti-epileptics for 14-days prior to the date of informed consent.
- Absolute neutrophil count ≥ 1,500/microliter
- Platelets ≥ 100,000/microliter
- Total bilirubin within normal institutional limits
- AST (SGOT) / ALT (SPGT) ≤ 2.5 x institutional upper limit of normal
- Creatinine clearance (CrCl) of \>60 mL/min (using the Cockcroft-Gault formula or 24- hour urine collection).
- Has not undergone a hysterectomy or bilateral oophorectomy; or
- Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has not had menses at any time in the preceding 12 consecutive months).
- A negative serum pregnancy test will be required of all female patients of child-bearing potential within seven days prior to the receipt of NEO212.
- A serum pregnancy test will be repeated immediately if pregnancy is suspected. Phase 1: (dose escalation)
- have radiographically confirmed Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype following previous radiation therapy or treatment with temozolomide and radiation, or
- have select solid tumors with uncontrolled metastases to the brain (confirmed by cranial CT or MRI) that is not controlled by surgery or radiation therapy and receiving one of the protocol approved SOC regimens.
- 28 days or 5 half-lives (whichever is shorter) elapsed from the administration from any experimental agent;
- 2 weeks from administration of immunotherapies;
- 28 days from administration of cytotoxic agents; and
- 7 days from administration of non-cytotoxic agents (interferon, tamoxifen, thalidomide, cis-retinoic acid, and herbal medicine). NOTE: No washout is necessary for alternating electrical fields. Phase 2a: (safety run-in)
- Patient must have select solid tumors with uncontrolled metastases to the brain (confirmed by cranial CT or MRI) that is not controlled by surgery or radiation therapy and receiving one of the protocol approved SOC...
- Patients receiving prior systemic therapy must be receiving one of the protocol approved Standard of Care (SOC) regimens.
- Patient must have measurable/evaluable CNS disease per RANO or RANO-BM criteria.
- Patient must have measurable/evaluable systemic disease per RECIST v1.1 criteria. Phase 2b: (how well it works)
- have radiographically confirmed Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype following previous radiation therapy or treatment with temozolomide and radiation, or
- have select solid tumors with uncontrolled metastases to the brain (confirmed by cranial CT or MRI) that is not controlled by surgery or radiation therapy and receiving one of the protocol approved SOC regimens.
- Patients receiving prior systemic therapy must be receiving one of the protocol approved Standard of Care (SOC) regimens.
- Patient must have measurable/evaluable CNS disease per RANO or RANO-BM criteria
- Patient with select solid tumors must have measurable/evaluable systemic disease per RECIST v1.1 criteria.
- Creatinine clearance (CrCl) of \>60 mL/min (using the Cockcroft-Gault formula or 24-hour urine collection).
What rules you out
- (all Phases)
- Patient in Phase 1 concurrently receiving any other antitumor therapy.
- Patient in Phase 2a or 2b who is concurrently receiving any SOC therapy not listed in Appendix 1.
- Patients with metastases to the spinal cord parenchyma.
- Patients with metastases to the meninges.
- Patient has received stereotactic or highly conformal radiotherapy to CNS lesions within 2 weeks before receipt of NEO212.
- Patient with history of known leptomeningeal involvement.
- Patient has prior history or new diagnosis of secondary cancer within five years prior to the date of informed consent, except for basal cell carcinoma or squamous cell carcinoma of the skin.
- Patient has a corrected QT interval (using Fridericia's correction formula) (QTcF) of \>470 msec, a history of additional risk factors for TdP (e.g.
- Patient had surgery within 7 days prior to the date of informed consent.
- Patient has not recovered to Grade 1 from treatment related adverse events due to chemotherapy, immunotherapy, or radiation therapy.
- Patient had prior treatment with perillyl alcohol.
- Patient has a history of allergic reactions attributed to perillyl alcohol.
- Patients in Phase 2b with Astrocytoma IDH-mutant, or Glioblastoma IDH-wildtype who have had more than one recurrence or progression of his/her primary CNS tumor(s).
The study team makes the final eligibility decision.
Where it is enrolling
- Beverly Hills, California, United States
- Glendale, California, United States
- Los Angeles, California, United States
- Boynton Beach, Florida, United States
- Boston, Massachusetts, United States
- Nashville, Tennessee, United States
- Dallas, Texas, United States
- Tacoma, Washington, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Beverly Hills, California, United States; Glendale, California, United States; Los Angeles, California, United States; Boynton Beach, Florida, United States; Boston, Massachusetts, United States; Nashville, Tennessee, United States and 2 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.